妇女在怀孕前或早孕时停止GLP-1药物的体重增加,并面临更高的怀孕风险。 Women stopping GLP-1 drugs before or early in pregnancy gained more weight and faced higher pregnancy risks.

对近150 000例怀孕进行的一项新研究发现,在怀孕前或早孕时停止使用GLP-1受体激动剂药物的妇女体重明显增加,而且与未接触者相比,妊娠糖尿病、高血压和早产的风险更高。 A new study of nearly 150,000 pregnancies found that women who stopped GLP-1 receptor agonist drugs before or early in pregnancy gained significantly more weight and faced higher risks of gestational diabetes, hypertension, and preterm birth compared to those not exposed. 覆盖2016年至2025年的回顾性分析显示,暴露女性的平均体重增加13. 7公斤,而未暴露女性的平均体重增加10. 5公斤,剖腹产和婴儿大小没有显著差异. The retrospective analysis, covering 2016 to 2025, showed exposed women gained an average of 13.7 kg versus 10.5 kg in unexposed women, with no significant differences in cesarean delivery or baby size. 大多数受感染的妇女患有肥胖症或原已存在的糖尿病。 Most exposed women had obesity or preexisting diabetes. 调查结果突出表明,需要更好地指导如何管理生殖年龄妇女的这些药物。 The findings highlight the need for better guidance on managing these medications in reproductive-age women.